Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB-DTK-CMV in Antiviral-Resistant and Refractory CMV Retinitis
NCT07679412Recruiting
- Sponsor
- LucasBio
- Start
- Apr 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of LB-DTK-CMV in cytomegalovirus retinitis, sponsored by LucasBio. Primary endpoints: Viral Load at 24 weeks, Clinical Symptom Assessment at 24 weeks and 2 more. Started Apr 2026; status: recruiting.
02
Drugs
LB-DTK-CMV
03
Conditions
cytomegalovirus retinitis
Beyond the preview
Go deeper on NCT07679412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07679412.